Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis Review uri icon

Overview

MeSH Major

  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Tumor Necrosis Factors

abstract

  • Discontinuation of anti-TNF therapy is achievable for many RA patients who start in clinical remission or LDA. However, heterogeneous inclusion criteria and highly variable outcome definitions across studies make it difficult to efficiently summarize the literature on this topic or to conduct a meta-analysis. There is a lack of evidence regarding how to best predict which patients have the greatest likelihood of continuing to do well after discontinuation of anti-TNF therapy.

publication date

  • November 2013

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3917677

Digital Object Identifier (DOI)

  • 10.1016/j.clinthera.2013.09.015

PubMed ID

  • 24156821

Additional Document Info

start page

  • 1850

end page

  • 61.e1

volume

  • 35

number

  • 11